S20 Relief and Safety to Pharmacogenomics ∼Can a Pharmacist Take the Responsibility for Management of Pharmacogenomics? ∼ S20-1 Significant effects of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for Japanese breast cancer patients S20-2 Issues for appropriate use of genetic information in drug therapy S20-3 Ethical, legal and social implications of direct-to-consumer PGx testing S20-4 “operational guideline of pharmacogenomics testing” and protection of personal genetic information S20-5 Importance of ethical education for pharmacists on their roles in pharmacogenomics